Nearly a decade after CRISPR gene-editing technology moved from laboratory research into clinical use, the treatments it has enabled remain out of reach for most patients worldwide, reigniting debate among scientists, policymakers and health economists over how to make the technology broadly accessible rather than limited to wealthy healthcare systems.
Gene editing allows scientists to correct or alter faulty DNA sequences responsible for inherited diseases, offering the prospect of one-time cures for conditions that previously required lifelong management. Since the first CRISPR-based therapies received regulatory approval, the technology has been hailed as one of the most significant medical breakthroughs of the century. Yet the same therapies that promise to cure debilitating genetic disorders often carry price tags that place them beyond the reach of most national health systems, let alone individual patients, particularly in low- and middle-income countries where the burden of many inherited diseases is highest.
Advocates for wider access argue that the current model, in which a small number of specialized centers in high-income countries administer expensive, logistically complex treatments, risks turning gene editing into a technology reserved for the few. Manufacturing gene therapies typically involves highly specialized facilities, cold-chain logistics and trained personnel, all of which add to costs that can run into the hundreds of thousands of dollars per patient. Without deliberate efforts to simplify manufacturing, lower costs and build treatment capacity in a wider range of countries, proponents of equitable access warn that gene editing could deepen existing health disparities rather than reduce them.
Why the Gulf Should Pay Attention
The equity question carries particular relevance for the UAE and wider Gulf region, where governments have made substantial investments in genomics and precision medicine as part of broader economic diversification and healthcare modernization strategies. The UAE has positioned itself as a regional hub for advanced biotechnology, backing large-scale population genome sequencing initiatives and building infrastructure intended to support cutting-edge therapies, including gene-based treatments for inherited and rare diseases that are relatively more prevalent in the region due to genetic factors.
For Gulf health authorities, the debate over gene-editing accessibility intersects directly with national health strategies that emphasize both innovation and universal access to advanced care. As regional governments continue to fund genomics programs and partnerships with international biotechnology firms, questions about the cost structure of gene therapies and the scalability of manufacturing are likely to shape how quickly these treatments reach patients in the GCC.
Industry observers note that the same challenges limiting global access, including complex manufacturing requirements, specialized clinical infrastructure and high per-patient costs, apply to healthcare systems in the Gulf as much as anywhere else, even in countries with significant public health budgets. This has prompted calls within the sector for collaborative models that could allow smaller or mid-sized health systems, including those in the GCC, to participate in clinical development and eventual distribution of gene therapies rather than relying solely on treatments developed and manufactured abroad.
As global conversations continue around making gene editing more broadly available, stakeholders across research, industry and government are being urged to consider new financing models, regional manufacturing partnerships and streamlined regulatory pathways that could bring these treatments closer to patients outside the handful of countries currently able to offer them. For the UAE and its neighbors, the outcome of that conversation could determine how quickly the region’s genomics investments translate into treatments available to patients at home.
